[go: up one dir, main page]

EA201492203A1 - Рекомбинантный ботулинический нейротоксин - Google Patents

Рекомбинантный ботулинический нейротоксин

Info

Publication number
EA201492203A1
EA201492203A1 EA201492203A EA201492203A EA201492203A1 EA 201492203 A1 EA201492203 A1 EA 201492203A1 EA 201492203 A EA201492203 A EA 201492203A EA 201492203 A EA201492203 A EA 201492203A EA 201492203 A1 EA201492203 A1 EA 201492203A1
Authority
EA
Eurasian Patent Office
Prior art keywords
rekombinantniy
neyrotoksin
botuliniçeskiy
disclosed
serotype
Prior art date
Application number
EA201492203A
Other languages
English (en)
Other versions
EA029275B1 (ru
Inventor
Минь Дун
Лишэн Пэн
Пол Эрик Густав Стенмарк
Ронни Пер-Арне Бернтссон
Original Assignee
Президент Энд Феллоуз Оф Гарвард Колледж
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Президент Энд Феллоуз Оф Гарвард Колледж filed Critical Президент Энд Феллоуз Оф Гарвард Колледж
Publication of EA201492203A1 publication Critical patent/EA201492203A1/ru
Publication of EA029275B1 publication Critical patent/EA029275B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

Раскрыты полипептиды ботулинического нейротоксина (BoNT), содержащие модифицированный рецептор-связывающий домен Clostridial botulinum серотипа В (В-Н), который содержит одну или несколько заместительных мутаций, соответствующих заместительным мутациям, присутствующим в серотипе В, штамм 1, V1118M; Y1183M; Е1191М; E1191I; E1191Q; Е1191Т; S1199Y; S1199F; S1199L; S1201V и их комбинациям. Конкретные комбинации мутаций включают Е1191М и S1199L, Е1191М и S1199Y, Е1191М и S1199F, E1191Q и S1199L, E1191Q и S1199Y или E1191Q и S1199F. Также описаны другие заместительные мутации. Также раскрыты выделенные модифицированные рецептор-связывающие домены, химерные молекулы, фармацевтические композиции и способы их применения.
EA201492203A 2012-05-30 2013-03-13 Рекомбинантный ботулинический нейротоксин EA029275B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261653214P 2012-05-30 2012-05-30
PCT/US2013/030737 WO2013180799A1 (en) 2012-05-30 2013-03-13 Engineered botulinum neurotoxin

Publications (2)

Publication Number Publication Date
EA201492203A1 true EA201492203A1 (ru) 2015-05-29
EA029275B1 EA029275B1 (ru) 2018-03-30

Family

ID=48050254

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201492203A EA029275B1 (ru) 2012-05-30 2013-03-13 Рекомбинантный ботулинический нейротоксин

Country Status (22)

Country Link
US (3) US9598685B2 (ru)
EP (2) EP3372239B1 (ru)
JP (3) JP6336970B2 (ru)
KR (1) KR102060355B1 (ru)
CN (2) CN104736166B (ru)
AU (2) AU2013267957B2 (ru)
BR (1) BR112014029585A2 (ru)
CA (3) CA2874587C (ru)
DK (2) DK3372239T3 (ru)
EA (1) EA029275B1 (ru)
ES (2) ES2661033T3 (ru)
HU (2) HUE037310T2 (ru)
IL (1) IL235934B (ru)
MX (2) MX359480B (ru)
NZ (1) NZ702310A (ru)
PL (2) PL3372239T3 (ru)
PT (2) PT3372239T (ru)
SG (2) SG10201606666XA (ru)
TR (1) TR201802754T4 (ru)
UA (1) UA116985C2 (ru)
WO (1) WO2013180799A1 (ru)
ZA (1) ZA201408757B (ru)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005019302A1 (de) * 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
ES2661033T3 (es) 2012-05-30 2018-03-27 President And Fellows Of Harvard College Neurotoxina botulínica genéticamente modificada
JP6156954B2 (ja) * 2012-11-21 2017-07-05 イプセン バイオイノベーション リミテッド タンパク分解性にプロセシングされたポリペプチドの製造方法
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US9913875B2 (en) * 2015-03-16 2018-03-13 California Institute Of Technology Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
CN115925835A (zh) * 2015-03-26 2023-04-07 哈佛大学校长及研究员协会 工程改造的肉毒杆菌神经毒素
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
JP7060522B2 (ja) 2016-05-16 2022-04-26 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ ボツリヌス神経毒素の精製及び活性化のための方法
CN109476713A (zh) * 2016-06-08 2019-03-15 儿童医学中心公司 工程改造的肉毒杆菌神经毒素
MA45492A (fr) 2016-06-23 2019-05-01 Hopitaux Paris Assist Publique Vecteurs viraux pour le traitement de l'hyperactivité vésicale neurogène
BR112019000278A2 (pt) * 2016-07-08 2019-04-24 Children's Medical Center Corporation neurotoxina botulínica e seus derivados
EP3504226A1 (en) * 2016-08-24 2019-07-03 President and Fellows of Harvard College Engineered botulinum neurotoxin
EP3312290A1 (en) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3641746B1 (en) 2017-06-19 2024-11-20 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
CN112105379A (zh) * 2017-09-29 2020-12-18 儿童医学中心公司 神经毒素样毒素及其用途
SG11202005757SA (en) * 2017-12-20 2020-07-29 Allergan Inc Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation
TWI810228B (zh) * 2017-12-20 2023-08-01 英商艾普森生物製藥有限公司 自主神經系統障礙之治療
CA3089834A1 (en) * 2018-01-30 2019-08-08 Children's Medical Center Corporation Production of botulinum neurotoxins using bacillus systems
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
SE542539C2 (en) * 2018-02-26 2020-06-02 Toxotech Ab Chimeric botulinum neurotoxin heavy chain binding domain
US20220016221A1 (en) 2018-12-05 2022-01-20 Ipsen Biopharm Limited Treatment of symptoms of traumatic brain injury
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202001353D0 (en) 2020-01-31 2020-03-18 Ipsen Biopharm Ltd Treatment of skin conditions
GB202003813D0 (en) 2020-03-16 2020-04-29 Ipsen Biopharm Ltd Treatment of upper facial lines
KR20220154738A (ko) 2020-03-16 2022-11-22 입센 바이오팜 리미티드 사지 경직을 치료하기 위한 변형된 보툴리눔 신경독소
GB202011055D0 (en) 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain
US20240016904A1 (en) * 2020-11-25 2024-01-18 Vetmed Therapeutics, Inc. Methods of treating superficial digital flexor tendon injuries, deep and superficial muscle/tendon contracture, navicular syndrome, and suspensory ligament inflammation and injuries in quadruped animals
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
BR112023020057A2 (pt) 2021-03-30 2024-03-12 Ipsen Biopharm Ltd Tratamento de dor e distúrbios inflamatórios
CN117396217A (zh) 2021-03-30 2024-01-12 益普生生物制药有限公司 无催化活性的梭菌神经毒素用于疼痛和炎性疾病的治疗
KR102547393B1 (ko) 2021-04-19 2023-06-23 엠브릭스 주식회사 보툴리늄 독소 전위 도메인 및 엔도라이신을 포함하는 단백질 복합체 및 이를 포함하는 항균 조성물
KR20240067070A (ko) 2021-09-16 2024-05-16 입센 바이오팜 리미티드 경부 이상긴장증의 치료에 사용하기 위한 변형된 bont/a
GB202113602D0 (en) 2021-09-23 2021-11-10 Ipsen Biopharm Ltd Treatment of a disorder affecting an eyelid muscle of a subject
EP4404955A1 (en) 2021-09-23 2024-07-31 Ipsen Biopharm Limited Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject
EP4436594A1 (en) 2021-11-22 2024-10-02 Ipsen Biopharm Limited Treatment of pain
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
CN114410683B (zh) * 2022-01-12 2023-11-28 中国人民解放军空军军医大学 一种基于Cre-lox重组系统的RIM3-RNAi及其应用
CN114369623B (zh) * 2022-01-12 2023-07-07 中国人民解放军空军军医大学 一种基于Cre-lox重组系统的Synaptotagmin2-RNAi及其应用
GB202206361D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of a facial dystonia
GB202206348D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of limb spasticity
GB202206362D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of upper facial lines
GB202206353D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of cervical dystonia
GB202213479D0 (en) 2022-09-14 2022-10-26 Ipsen Biopharm Ltd Cell-free clostridial neurotoxin assays
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
CN119823215A (zh) * 2023-10-13 2025-04-15 北京博特维克生物技术有限公司 高效快速重组表达神经毒素蛋白的多肽及其方法
WO2025093845A1 (en) 2023-11-01 2025-05-08 Ipsen Biopharm Limited Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines
WO2025093844A1 (en) 2023-11-01 2025-05-08 Ipsen Biopharm Limited Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation
GB202320108D0 (en) 2023-12-28 2024-02-14 Ipsen Biopharm Ltd Biosensor
GB202404021D0 (en) 2024-03-20 2024-05-01 Ipsen Biopharm Ltd Cell-based neurotoxin assay
CN118388606B (zh) * 2024-04-25 2025-09-23 武汉大学 一种结合蛋白Bntifitin及其在制备用于治疗冠状病毒感染的药物中的应用
KR102790255B1 (ko) * 2025-01-23 2025-04-07 엠브릭스 주식회사 재조합 보툴리눔 독소 및 이를 함유하는 약학 조성물
CN120775067A (zh) * 2025-07-07 2025-10-14 西北农林科技大学 一种毒性增强型神经毒素重组蛋白

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5053005A (en) 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
DK0758900T3 (da) 1994-05-09 2002-07-29 William J Binder Botulinumtoksin til reduktion af migræne-hovedpinesmerter
DE69511860T2 (de) 1994-05-31 2000-02-10 Allergan, Inc. Modifizierung von clostridium-toxinen und ihre anwendung als transport proteine
GB9411138D0 (en) 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5721215A (en) 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
EP1105153A4 (en) * 1996-08-28 2005-01-19 Ophidian Pharm Inc POLYVALENT VACCINE AGAINST NEUROTOXIN (CLOSTRIDIUM BOTILINUM)
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US20040033241A1 (en) 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US7148041B2 (en) 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
CA2558758C (en) 2004-02-24 2015-06-23 Allergan, Inc. Botulinum toxin screening assays
KR100668570B1 (ko) 2004-06-28 2007-01-16 입센 리미티드 복재신경 포착에 의한 무릎 관절 통증 치료를 위한,보툴리눔 독소를 포함하는 제약 조성물
DE102004043009A1 (de) * 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
US8052979B2 (en) 2005-03-15 2011-11-08 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
US7985554B2 (en) 2005-10-14 2011-07-26 Wisconsin Alumni Research Foundation Botulinum neurotoxin A receptor and the use thereof
DE102005051789B4 (de) 2005-10-28 2014-08-07 Toxogen Gmbh Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
FR2907680B1 (fr) 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
US8586081B2 (en) 2007-09-20 2013-11-19 University Of Massachusetts Detoxified recombinant botulinum neurotoxin
WO2009042165A2 (en) 2007-09-25 2009-04-02 Thomas Jefferson University Mutant botulinum neurotoxin serotype a polypeptide and uses thereof
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
EP2337790B1 (en) 2008-08-29 2016-07-13 Merz Pharma GmbH & Co. KGaA Clostridial neurotoxins with altered persistency
CN101386648B (zh) * 2008-09-25 2012-05-30 中国人民解放军军事医学科学院微生物流行病研究所 抗b型肉毒神经毒素中和性单克隆抗体、其制备方法及用途
US20100196445A1 (en) 2008-11-12 2010-08-05 David Nathaniel E Systems and methods for delivery of biologically active agents
CN102481351B (zh) * 2009-04-14 2015-05-13 Mcw研究基金会股份有限公司 工程改造的肉毒杆菌神经毒素
US8440204B2 (en) 2009-04-30 2013-05-14 Wisconsin Alumni Research Foundation Subtype of Closteridium botulinum neurotoxin type A and uses thereof
ES2661033T3 (es) 2012-05-30 2018-03-27 President And Fellows Of Harvard College Neurotoxina botulínica genéticamente modificada
CN115925835A (zh) 2015-03-26 2023-04-07 哈佛大学校长及研究员协会 工程改造的肉毒杆菌神经毒素
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
CN109476713A (zh) 2016-06-08 2019-03-15 儿童医学中心公司 工程改造的肉毒杆菌神经毒素
EP3504226A1 (en) 2016-08-24 2019-07-03 President and Fellows of Harvard College Engineered botulinum neurotoxin

Also Published As

Publication number Publication date
CN108178801A (zh) 2018-06-19
EP2854840A1 (en) 2015-04-08
PT3372239T (pt) 2021-02-02
ES2847241T3 (es) 2021-08-02
AU2018200409B2 (en) 2019-10-10
CN104736166B (zh) 2018-02-16
MX359480B (es) 2018-09-28
CN108178801B (zh) 2022-05-03
KR102060355B1 (ko) 2019-12-31
EP3372239A1 (en) 2018-09-12
CA3170993A1 (en) 2013-12-05
TR201802754T4 (tr) 2018-03-21
PL3372239T3 (pl) 2021-05-04
KR20150029656A (ko) 2015-03-18
JP6839239B2 (ja) 2021-03-03
US10190110B2 (en) 2019-01-29
JP6336970B2 (ja) 2018-06-06
MX2014014540A (es) 2015-02-24
JP6574218B2 (ja) 2019-09-11
AU2013267957A1 (en) 2014-12-18
UA116985C2 (uk) 2018-06-11
SG10201606666XA (en) 2016-09-29
EA029275B1 (ru) 2018-03-30
CN104736166A (zh) 2015-06-24
HK1210692A1 (en) 2016-05-06
US20190256834A1 (en) 2019-08-22
CA2874587C (en) 2022-11-08
JP2015519362A (ja) 2015-07-09
AU2018200409A1 (en) 2018-03-01
PL2854840T3 (pl) 2018-07-31
IL235934A0 (en) 2015-01-29
DK2854840T3 (en) 2018-03-05
US20170226496A1 (en) 2017-08-10
EP3372239B1 (en) 2020-11-11
ZA201408757B (en) 2018-05-30
ES2661033T3 (es) 2018-03-27
EP2854840B1 (en) 2018-01-17
WO2013180799A9 (en) 2014-12-24
JP2017212975A (ja) 2017-12-07
DK3372239T3 (da) 2021-02-01
US20150166972A1 (en) 2015-06-18
AU2013267957B2 (en) 2017-10-19
IL235934B (en) 2020-04-30
JP2019216735A (ja) 2019-12-26
US9598685B2 (en) 2017-03-21
MX2018011854A (es) 2020-09-02
NZ702310A (en) 2016-08-26
PT2854840T (pt) 2018-03-02
CA3248592A1 (en) 2025-11-29
HUE053147T2 (hu) 2021-06-28
SG11201407784UA (en) 2014-12-30
WO2013180799A1 (en) 2013-12-05
HUE037310T2 (hu) 2018-08-28
BR112014029585A2 (pt) 2017-07-25
US10844362B2 (en) 2020-11-24
CA2874587A1 (en) 2013-12-05

Similar Documents

Publication Publication Date Title
EA201492203A1 (ru) Рекомбинантный ботулинический нейротоксин
EA201892784A1 (ru) Сконструированные ботулинические нейротоксины
SA520420658B1 (ar) جزيئات ربط ضد bcma واستخداماتها
MX389789B (es) Moléculas del receptor de envolvimiento quimérico.
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
UY33588A (es) Moleculas de union a vegf
BR112019000278A2 (pt) neurotoxina botulínica e seus derivados
CA2816976A1 (en) Optogenetic control of reward-related behaviors
UA116632C2 (uk) Химерний білок, який містить фактор viii та фактор віллебранда, і його застосування
MX385834B (es) Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos.
UY32917A (es) Moléculas de unión a dll-4
MX2015006548A (es) Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2.
BR112014024282A2 (pt) anticorpos ligantes ao receptor b1 da bradicinina
NO20093009L (no) Kondensert ring heterocykel kinase modulatorer
MX374682B (es) Moléculas de unión a 4-1bb.
AR090158A1 (es) Polipeptidos de union a cx3cr1
BR112014032910A2 (pt) solfactants de éter de glicerina etoxilado
NZ703546A (en) Composition comprising a mixture of cd95-fc isoforms
BR112014023415A2 (pt) moléculas que se ligam a ang2
EA201991409A2 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
BR112015024758A2 (pt) proteínas de fusão de ligação à cartilagem
BR112015014727B8 (pt) Composição imunogênica, vacina, e, uso de uma composição imunogênica
AR085919A1 (es) Moleculas de union bioespecificas que se unen a ligando 4 de tipo delta (dii4) y angiopoyetina 2 (ang2)
NZ702285A (en) Staphylococcal coagulase antigens and methods of their use
EA201200545A1 (ru) Производные пиразола, которые модулируют стеароил-соа десатуразу